ApoAI Polyclonal Antibody
Cayman Chemical Item Number 10008463
Apolipoprotein A-I; Apolipoprotein AI
ApoAI Polyclonal Antibody
Description
Antigen:
human ApoA1 protein amino acids 188-199 (RLAEYHAKTEH)
·
Host:
rabbit
·
Application(s):
WB and ICC; other applications not tested
·
ApoA1 is a major protein component in high-density lipoproteins (HDL). It acts as an acceptor for sequential transfers of phospholipids and free cholesterol from peripheral tissues as well as transporting cholesterol to the liver and other tissues for excretion and steroidogenesis.1 Serum ApoA1 levels are inversely related to the risk of developing atherosclerosis.2 Loss-of-function mutations in ApoA1 are causes of diseases such as HDL deficiency type 1 (or Tangier disease) and type 2 (familial hypoalphalipoproteinemia), and systemic non-neuropathic amyloidosis.3,4 Liver and small intestine are two main sources of the protein. ApoA1 is comprised of a single polypeptide chain of 243 amino acid residues with an estimated molecular weight of 28 kDa. Cayman’s ApoA1 polyclonal antibody detects the protein by western blot analysis in tissue/cell samples such as liver, intestine, and Hep-G2 cells. The antibody can also be used for immunocytochemistry.
1
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
2
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
3
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
4
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
| Synonyms |
- Apolipoprotein A-I
- Apolipoprotein AI
|
| Formulation |
Peptide affinity-purified IgG |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
Wet ice
in continental US; may vary elsewhere
|
| Specificity |
| Human ApoA1 |
+ |
| Mouse ApoA1 |
+ |
| Rat ApoA1 |
+ |
|
Background Reading
Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 103(7) 2126-2131 (2006).
Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 91 522-529 (1993).
Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of apoA1 gene expression with acidosis: Requirement for a transcriptional repressor. J Mol Endocrinol 27 43-57 (2001).
Tall, A.R., and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106(10) 1205-1207 (2000).
Show all 4
Hide all but first 3
|
Pricing updated 2012-05-25.
Prices are subject to change without notice.
To ask for assistance with one of our products please contact a Technical Support Scientist.
Warning This product is not for human or veterinary use.
Show all 7
Hide all but first 3
Downloads
Batch-specific Information
Login
to access batch-specific information
|